Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 9/20 | 0.36 |
| ▸ | TYK2 | P29597 | 9/20 | 0.36 |
| ▸ | JAK3 | P52333 | 9/20 | 0.36 |
| ▸ | JAK2 | O60674 | 8/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19533304 | 0.87 | JAK1 (0.34) | JAK1TYK2JAK3JAK2FGFR1 | |
| SCHEMBL19533290 | 0.71 | CDK8 (0.34) | — | |
| SCHEMBL19533708 | 0.71 | PARP1 (0.36) | FGFR1KCNH2 | |
| SCHEMBL19533295 | 0.70 | IDO1 (0.37) | — | |
| SCHEMBL15450891 | 0.68 | KDM4E (0.31) | — | |
| SCHEMBL19533296 | 0.68 | PDE4A (0.41) | LMNA | |
| SCHEMBL19624752 | 0.67 | FGFR1 (0.34) | FGFR1KCNH2 | |
| SCHEMBL19624893 | 0.66 | PDPK1 (0.39) | JAK1TYK2JAK3JAK2FGFR1 | |
| SCHEMBL19533297 | 0.65 | ALOX15 (0.33) | BRD4 | |
| SCHEMBL19533307 | 0.64 | FGFR1 (0.39) | JAK1TYK2JAK3JAK2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662174-B2 | BTK inhibitor | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| EP-3246317-A1 | BTK INHIBITOR | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-11-22 | — | — | EP | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662174-B2 | BTK inhibitor | BTK, SYK, LYN | JAK1 19/4885TYK2 12/4885JAK3 80/4885 |
| US-20170313683-A1 | BTK INHIBITOR | BTK, SYK, LYN | JAK1 19/4885TYK2 12/4885JAK3 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.